Detail akcie Astra Zeneca online

Business Summary: AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, AstraZeneca plc revenues increased 18% to $54.07B. Net income increased 18% to $7.04B. Revenues reflect Farxiga segment increase of 28% to $7.66B, Ultomiris segment increase of 32% to $3.92B, Tagrisso segment increase of 13% to $6.58B, United States segment increase of 20% to $21.81B, United Kingdom segment increase of 41% to $4.74B, Sweden segment increase of 34% to $2.29B.